Please login to the form below

Not currently logged in
Email:
Password:

Nordics investigate vaccine narcolepsy link

Sweden and Finland have opened inquiries into whether the GSK swine flu vaccine Pandemrix is responsible for cases of narcolepsy in children

Läkemedelsverket, Sweden's Medical Products Agency (MPA), and Finland's National Institute for Health and Welfare (THL) have begun investigating if the GlaxoSmithKline (GSK) vaccine Pandemrix is responsible for cases of narcolepsy among children treated with the H1N1 "swine flu" drug. The investigations have been launched in response to physician reports.

The MPA has received six reports from healthcare professionals regarding narcolepsy as a suspected adverse drug reaction following Pandemrix flu vaccination," the Agency said in a statement.

These reports concern children aged 12-16 years who developed symptoms of narcolepsy within two months of inoculation with Pandemrix.

In Finland, the number of narcolepsy cases reported this year was 12-14, which is much higher than the average of three cases annually. This increase has prompted officials there to consider a link between the condition and either the vaccine or the flu itself. 

The Finnish cases were detected among children aged 5-15 years. Symptoms began between December and February, during the winter 2009/10 flu season, and the cases were diagnosed in early spring and summer.

Kerhi Kilpi, the director of THL's vaccine department, has said that she does not believe a link exists but that any doubts must be examined.

Preliminary results from the investigations are expected by the end of the year.

19th August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...